OCGN Reports $112.1M Cash, $115M 6.75% Convertible Notes, Phase 3 GA Trial Shows 31% Lesion Reduction, 20% No Progression, 75% >30% Iesion Shrinkage, BLA Targets 2027, Cash Runway to 2028
Ocugen, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $1.37
-2.3% in 1d after detection
Post-detection moves
1h
—
1d
-2.3%
3d
+1.3%
7d
-2.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS